Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Membranous nephropathy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Membranous nephropathy. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-001647-19 Sponsor Protocol Number: 2008.1 Start Date*: 2008-05-22
    Sponsor Name:Radboud University Nijmegen Medical Center
    Full Title: Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study.
    Medical condition: Membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002985-15 Sponsor Protocol Number: MOR202C205 Start Date*: 2020-10-12
    Sponsor Name:MorphoSys AG
    Full Title: A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (N...
    Medical condition: Anti-PLA2R antibody positive membranous nephropathy (aMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000835-30 Sponsor Protocol Number: MONET Start Date*: 2021-10-12
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: RESCUE THERAPY WITH THE HUMAN ANTI-CD38 ANTIBODY MOR202 (FELZARTAMAB) IN PATIENTS WITH MEMBRANOUS NEPHROPATHY WHO FAILED ANTI-CD20 TARGETED THERAPY: A PILOT, PROOF-OF-CONCEPT STUDY
    Medical condition: Membranous Nephropathy who Failed Anti-CD20 Target Therapy.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004864-81 Sponsor Protocol Number: ORION Start Date*: 2021-12-17
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Proposta di studio per valutare l’efficacia di Obinutuzumab, un anticorpo anti-CD20, in pazienti con nefropatia membranosa intolleranti, resistenti o dipendenti alla terapia con Rituximab (studio O...
    Medical condition: PRIMARY MEMBRANOUS NEPHROPATHY
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002476-40 Sponsor Protocol Number: 17-APN-01 Start Date*: 2019-05-07
    Sponsor Name:CHU de Nice
    Full Title: Personalized Medicine for Membranous Nephropathy PMMN
    Medical condition: Idiopathic Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006115-59 Sponsor Protocol Number: GNM-2011 Start Date*: 2012-06-11
    Sponsor Name:AZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
    Full Title: "A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy (IMN)"
    Medical condition: MN is an autoimmune disease, suggesting that the disease may be triggered by isotype specific autoantibodies directed against podocyte enzymes and podocyte receptors that are recognized as antigens...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10018372 Glomerulonephritis membranous PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005410-39 Sponsor Protocol Number: MEMTAC Start Date*: 2008-06-11
    Sponsor Name:Grupo Catalán de Estudio de enfermedades glomerulares. Sociedad Catalana de nefrología.
    Full Title: “Estudio piloto aleatorizado comparativo de tacrolimus vs ciclofosfamida-prednisona en la nefropatía membranosa idiopática”
    Medical condition: La nefropatía membranosa idiopática (NMI) es una enfermedad caracterizada histopatológicamente por un engrosamiento uniforme de la pared de los capilares glomerulares, debido al depósito de complej...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027170 Membranous nephropathy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000226-55 Sponsor Protocol Number: STARMEN01-2013 Start Date*: 2014-04-16
    Sponsor Name:Fundacion Renal Iñigo Alvarez Toledo
    Full Title: European Multicenter and Open-Label Controlled Randomized Trial to evaluate the Efficacy of Sequential Treatment with Tacrolimus-Rituximab versus Steroids plus Cyclophosphamide in patientes with Pr...
    Medical condition: Primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005855-19 Sponsor Protocol Number: BCX9930-211 Start Date*: 2021-10-11
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: An Open-Label, Safety, Tolerability, and Proof-of-Concept Study of Oral BCX9930 Therapy in Subjects with Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, or Primary Membranous Nephropathy
    Medical condition: complement 3 glomerulopathy immunoglobulin A nephropathy primary membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-003233-38 Sponsor Protocol Number: WA41937 Start Date*: 2021-03-02
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL ACTIVE COMPARATOR-CONTROLLED MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH PRIMARY MEMBRANOUS NEPHROPATHY
    Medical condition: Primary Membranous Nephropathy (pMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000385-38 Sponsor Protocol Number: BEL116472 Start Date*: 2012-05-18
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: BEL116472. A 2 year mechanistic study of belimumab in Idiopathic Membranous Glomerulonephropathy
    Medical condition: Idiopathic Membranous Glomerulonephropathy (IMGN)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000242-38 Sponsor Protocol Number: BEL114674 Start Date*: 2013-01-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: BEL114674: A 2 year study of efficacy and safety of intravenous belimumab versus placebo in subjects with idiopathic membranous nephropathy
    Medical condition: Idiopathic Membranous Nephropathy (IMN)
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000780-24 Sponsor Protocol Number: MOR202C103 Start Date*: 2019-09-24
    Sponsor Name:MorphoSys AG
    Full Title: A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in anti-PLA2R antibody positive Membranous Nephropathy (aMN) - M-PLACE
    Medical condition: Primary (anti-PLA2R antibody positive) Membranous Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000971-18 Sponsor Protocol Number: SynAct-CS003 Start Date*: 2020-05-28
    Sponsor Name:SynAct Pharma ApS
    Full Title: An exploratory, randomized, double-blind, multicenter, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of AP1189 daily doses versus placebo administered ...
    Medical condition: Idiopathic membranous nephropathy and severe proteinuria
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10027170 Membranous nephropathy LLT
    21.1 10038359 - Renal and urinary disorders 10029164 Nephrotic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001734-34 Sponsor Protocol Number: CLNP023D12201 Start Date*: 2019-09-23
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, treatment open-label, dose-blinded, parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatmen...
    Medical condition: Idiopathic Membranous nephropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-004469-40 Sponsor Protocol Number: 5022005 Start Date*: 2006-05-12
    Sponsor Name:Hopital Erasme
    Full Title: Multicenter, pilot, open, randomized, parallel group study to evaluate the association of Neoral with ACE-inhibitors as compared to ACE-inhibitors alone in the treatment of de novo nephrotic syndro...
    Medical condition: Membranous Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001212-29 Sponsor Protocol Number: Prot-0824-2019 Start Date*: 2020-08-26
    Sponsor Name:Aarhus University Hospital, Henrik Birn
    Full Title: Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome
    Medical condition: Nephrotic syndrome is defined as severe proteinuria (> 3.5 g / day), edema and hypoalbuminemia. It is conditioned by a defect in the kidney's glomerular filtration barrier, resulting in the loss of...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10029167 Nephrotic syndrome with lesion of membranous glomerulonephritis LLT
    20.0 100000004857 10029165 Nephrotic syndrome in diseases classified elsewhere LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002004-33 Sponsor Protocol Number: FCRD01 Start Date*: 2007-08-15
    Sponsor Name:Encysive Pharmaceuticals Inc
    Full Title: The effects of sitaxsentan once daily dosing on proteinuria, 24 hour systemic blood pressure and arterial stiffness in subjects with chronic kidney disease.
    Medical condition: Chronic Kidney Disease (CKD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003884-12 Sponsor Protocol Number: EXTRAStudy Start Date*: 2015-12-22
    Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
    Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext...
    Medical condition: Extracapillary glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018376 Glomerulonephritis proliferative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001434-19 Sponsor Protocol Number: 1378.5 Start Date*: 2021-12-24
    Sponsor Name:Boehringer Ingelheim SComm
    Full Title: Randomised, double-blind, placebo-controlled and parallel dose group trial to investigate efficacy and safety of multiple doses of oral BI 690517 over 14 weeks, alone and in combination with empagl...
    Medical condition: chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) IT (Completed) NO (Completed) SE (Completed) CZ (Completed) HU (Completed) ES (Ongoing) DK (Prematurely Ended) BG (Completed) GR (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 11 08:21:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA